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Persistent patent ductus arteriosus (PDA) is very common in preterm infants, especially
in extremely preterm infants. Despite significant advances in management of these
vulnerable infants, there has been no consensus on management of PDA—when should
we treat, who should we treat, how should we treat and in fact there is no agreement
on how we should define a hemodynamically significant PDA. Medical management
with non-steroidal anti-inflammatory drugs (NSAIDs) remains the first line of therapy with
moderate success rate in closing the PDA. Paracetamol has been reported to be a safe
and equally effective medical therapy for closure of PDA. However, additional studies on
its long-term safety and efficacy in extremely low birth weight infants are needed before
paracetamol can be recommended as standard treatment for a PDA in preterm infants.
Surgical ligation of PDA is not without an increased risk of mortality and co-morbidities.
Recently, there has been a significant interest in percutaneous transcatheter closure of
PDA in preterm infants, including extremely low birth weight infants. Transcatheter PDA
closure in preterm ELBW infants is technically feasible with high PDA occlusion success
rates and acceptable complication rates as compared to surgical ligation. Many centers
have reported promising early- and mid-term follow-up results. However, they need to be
further tested in the prospective well-designed studies and randomized controlled trials
comparing the results and outcomes of this technique with current treatment strategies
including medical treatment before they can be used as the new standard of care for
PDA closure in extremely low birth weight infants.
Keywords: patent ductus arteriosus, prematurity, transcatheter closure, patent ductus arteriosus (PDA), extremely
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INDICATIONS AND CONVENTIONAL TREATMENT OF A
HEMODYNAMIC SIGNIFICANT PDA IN EXTREMELY LOW BIRTH
WEIGHT INFANTS
A persistent patent ductus arteriosus (PDA), defined as failure of the ductus to close within 72 h
postnatally, is very common in extremely low birth weight infants and seen in around 50% of infants
born under 28 weeks of gestation and / or birth weight <1,000 g (1). Preterm infants under 1,500 g
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are categorized as very low birth weight infants and those under
1,000 g are considered as extremely low birth weight (ELBW)
infants (1, 2). The pathophysiology and echocardiographic
diagnosis have been covered in the different articles of Frontier’s
Research topic on “management of PDA in preterm infants” and
this article is primarily focused at advances in management via
transcatheter closure of PDA in preterm infants weighing under
1,500 g. This article is not focused at whether we should treat or
not treat PDA but on the feasibility of closing PDA in ELBW
infants via transcatheter route when required as an alternative to
surgical ligation.
The left to right shunt across a persistent PDA may lead
to pulmonary over-circulation and left heart volume-overload
(2). Delayed closure of a hemodynamically significant PDA
has been reported to be associated with increased risk of
bronchopulmonary dysplasia (BPD) / chronic respiratory disease
(CLD), prolonged assisted ventilation, necrotizing enterocolitis
(NEC), pulmonary hemorrhage, intraventricular hemorrhage
(IVH), renal impairment and increased risk of mortality (2–10).
This association led to numerous (more than 60) randomized
controlled trials (RCTs) trying to prove that the treatment of
PDA would be beneficial. However, these trials have failed to
demonstrate any improvement in the long term outcomes such
as death or BPD / CLD (11). Some trials have reported short
term benefits such as early prophylactic use of indomethacin
reported reduction of IVH and acute pulmonary hemorrhage
and prophylactic surgical ligation reported reduction in NEC
(12–14). There are no other proven benefits shown in terms of
improvement in long-term outcomes (such as death or BPD)
and there are some adverse outcomes [e.g., increased incidence
of chronic lung disease was reported in infants treated with
ibuprofen (11)].
Despite the reported association between persistent PDA,
increased risk of mortality and significant co-morbidities, the
treatment strategy remains controversial which could be because
of proven benefits from treating the PDA in ELBW infants
(11, 15, 16). There is no agreed consensus on management of
PDA in preterm infants and there are numerous trials on-going
at the moment testing different treatment approaches to placebo
or no treatment.
Treatments with non-steroidal anti-inflammatory drugs
(NSAIDs) or paracetamol have been used to promote closure
when a PDA was found to be hemodynamically significant.
NSAIDs, cyclo-oxygenase inhibitors, have moderate success rate
in closing the PDA and they may have adverse effects in
some infants or even may be contraindicated in presence of
certain conditions such as NEC or intestinal perforation and
significant renal impairment (17, 18). Medical treatment fails in
20–40% of the cases (19, 20). Following a recent systemic review
(2020) by Ohlsson et al., concluded that paracetamol appears
to be a promising alternative to indomethacin and ibuprofen
for the closure of a PDA with possibly fewer adverse effects.
A possible association between prenatal paracetamol and the
development of autism or autism spectrum disorder in childhood
and language delay in girls has been reported (21). Therefore,
additional studies on its long-term safety and efficacy in ELBW
infants are needed before paracetamol can be recommended
as standard first line treatment for closure of PDA in preterm
infants (21).
Surgical ligation of the PDA is often the alternative to failed
pharmacological treatment and it is usually performed through
left thoracotomy. It is not without the increased risk of mortality
and significant morbidities in this vulnerable group of infants.
Thirty days mortality rate has been reported around 5–8%
(22, 23). Surgical ligation been reported to be associated to
post-ligation cardiac syndrome (PLCS), phrenic nerve and vocal
cord palsy, pneumothorax, bleeding, and infection (24–26).
The post-operative course of preterm infants undergoing
surgical ligation of PDA is often complicated by PLCS and
despite targeted milrinone prophylaxis, some infants continue
to experience hemodynamic instability and postoperative
respiratory deterioration (27–30). Studies have also that it may
also worsen long-term outcomes, including increasing the risk
for bronchopulmonary dysplasia, retinopathy of prematurity
and neurosensory impairment, however, controversies remain
whether these are related to surgical ligation or prolonged
exposure of preterm infants to PDA itself or associated
co-morbidities (31–33).
Conservative management approach, consisting of fluid
restriction, diuretics and positive end-expiratory pressure, is
also being practiced in many neonatal units because of the
lack of proven long-term benefits from PDA closure in
this population (34–37). Many studies have concluded that
conservative management approach is a reasonable option
as compared to pharmacologic or surgical treatment (35–41)
while some studies have questioned about the safety of this
approach because of increased mortality and morbidity (8, 9,
15). Results from RCTs and well-designed prospective studies
are awaited to establish risks and benefits of the conservative
management approach.
In absence of proven long term benefits from treating PDAs
and lack of superiority of one approach to another, currently
there is no universal consensus on how best PDA should
be managed in preterm infants. However, there is consensus
among the neonatal community that well-designed prospective
randomized controlled trials of different modalities against
placebo are needed, and there are more than 10 large randomized
trials of different approaches on-going worldwide (42). This
would be interesting to see the results of these trials in the
coming years.
Recently there has been an increased interest in
transcutaneous closure of PDA, whether this approach can
be used as an alternative to surgical ligation or even to medical
treatment in the ELBW infants. We describe the background,
current evidence and feasibility of this approach in closure of
PDA in infants under 1,500 g.
TRANSCATHETER CLOSURE OF PDA IN
EXTREMELY PRETERM INFANTS:
BACKGROUND
In the most recent years, several cohort studies reported
preliminary experience with transcatheter technique, using
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various devices for PDA closure in premature infants (43–55).
Comparison with surgical ligation revealed a positive impact on
post procedure pulmonary outcome (49, 50). The procedure has
been well-described in preterm infants, including extremely low
birth weight (ELBW) infants as small as 640 g (50). Following
the results of an ongoing prospective trial using the ADO II
AS, this device received FDA and CE approval for transcatheter
closure of PDA in premature babies weighting more than 700 g
and over 3 days old (51). This has been renamed as Amplatzer
Piccolo Occluder R© (APO). More recently, a retrospective
comparison between surgery and transcatheter closure by Regan
et al. reported an increased mechanical ventilation duration
during the NICU stay after surgery as compared to infants
undergoing transcatheter closure. Additionally, hospital stay
could potentially be shorter in cases where transcatheter closure
was performed in the 1st month of life (52).
PATIENT SELECTION AND ORGANIZATION
OF THE PROCEDURE
Preterm infants are always referred by neonatologist for
percutaneous closure, usually after failure of medical therapy
or when medical pharmacotherapy is contraindicated and/or
failure to wean from the ventilator. Pre-procedure transthoracic
echocardiography confirms the hemodynamic significance
(left cavities dilation, functional mitral/aortic regurgitation,
and ductal morphology) and transcatheter closure is usually
performed in catheterization laboratory. In most centers the
procedure is performed in the cardiac catheter lab, although
in some centers with portable fluoroscopy equipment the
procedure can be performed at the bedside, especially in very
unstable patients unsafe to move or when there is no access to
cardiac catheterization lab. Transcatheter closure at the bedside
under echocardiography guidance-only has also been reported
(44). Unfortunately, bedside procedure under echocardiography
guidance has to be performed via trans-arterial route (femoral
route) without fluoroscopy which carries increased risk of
potentially severe life-threatening complications such as limb
ischemia and more worryingly it has limited management
options for disc embolization if it occurs (56). Hence, despite
technical feasibility it is almost never performed on bedside in
ELBW infants and smallest reported infant having this procedure
successfully done was around 1,400 g. In comparison, when
percutaneous PDA closure performed in in the catheter lab it has
been performed successfully in infants as small as 700 g (50–52).
AVAILABLE DEVICES
Over the last few years, different devices have been used
to close PDAs in premature babies (Figure 1). PDA coil-
occlusion was initially achieved in selected low-weight infants
with symptomatic PDA (44, 51). More recently, the Amplatzer
Vascular Plug II (AVP II) was successfully implanted with good
results (43, 50, 54). Unfortunately, this device is often not suitable
for short ducts in extremely low-weight infants. In such cases
the central disk, which is the same diameter than the proximal
and distal disk can stretch and make the whole device too long,
increasing the risk of LPA and/or aortic stenosis. The Amplatzer
Vascular Plug IV has also been used but its length is also a
limiting factor in extremely small infants (55). Similarly, the
retention disks of the Amplatzer duct occluder II are too large
for infants weighing <1,500 g. The Medtronic Micro Vascular
Plug R© (MVP), initially designed for occlusion of abnormal blood
vessels, has shown excellent results for PDA closure in premature
babies (47, 50). It is made of a nitinol framework covered partially
by a polytetrafluoroethylene (PTFE) membrane at the proximal
portion. It is delivered through a microcatheter with two sizes of
5.3 and 6.5mm. The APO is currently the only dedicated device
for this procedure. It is a self-expanding occlusion device with a
central waist and retention disc on both ends, delivered through
a 4-French delivery catheter. The largest size of the distal disks is
6.5mm whereas the central waist is available in 3, 4, and 5mm
diameter and the length of the central waist varies between 2, 4,
and 6mm. Catheter and sheath diameters aremeasured in French
(Fr) units and 1Fr = 1/3mm or 0.013 inch. Wire diameter is
measured in inches; 0.014, 0.018, and 0.021 wires are 0.014, 0.018,
and 0.021 inch in diameter, respectively (49, 52).
DESCRIPTION OF THE PROCEDURE
Ultrasound-guided access of the femoral vein increases the
likelihood of successful access and reduces the risk of local
complications, especially inadvertent puncture of the femoral
artery. Femoral artery access is not recommended and even
contraindicated in extremely premature babies due to a high risk
for vessel occlusion and potential ischemia of the lower limb (57).
Aortic angiogram after device deployment is unnecessary when
appropriate echocardiographic guidance can be performed. A 4Fr
sheath is usually inserted in the femoral vein.
Heparin administration remains controversial (58). Whereas,
some operators give no heparin, others would give 50–100
units/kg of unfractionated heparin bolus once access has been
achieved. Prophylactic antibiotics are administered.
Under fluoroscopic guidance, a 3Fr multipurpose BALT
catheter (Montmorency, France) is usually advanced over a 0.014
coronary wire through the inferior vena cava toward the right
atrium. The coronary wire is advanced via right ventricle outflow
tract and through the patent ductus arteriosus toward descending
aorta. The 3Fcatheter is positioned in the descending aorta.
Sathanandam et al. have reported a similar technique using a
4Fr angled glide catheter (Terumo, Japan) and a 0.035 Wholey
wire (Medtronic, Minneapolis, MN, USA) to cross the PDA
antegradely into the descending aorta (59). Other teams have
used 4Fr Swan Ganz catheter instead of catheters described
above (43).
If a 3Fr catheter is used to cross the PDA, then a 0.021 Fixed-
Core Guide Wire (Cook Medical R©, USA) is advanced in the
descending aorta and the 3Fr catheter is directly exchanged with
the 4Fr TorqVue R© delivery sheath. This latest is often advanced
over a microcatheter to minimize mismatch with the 0.021 wire.
The tip of the TorqVue R© sheath is placed in the descending
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FIGURE 1 | Devices generally used for percutaneous PDA closure in premature babies. (A) Amplatzer Ductus Occluder II Additional Sizes / Piccolo Occluder (Abbott).
(B) Amplatzer vascular plug II (Abbott). (C) MVP Microvascular Plug (Medtronic).
FIGURE 2 | Most common ductal morphology in premature babies undergoing percutaneous closure. (A,B) Showing type “C” tubular ductus without any
constrictions at the aortic end or the pulmonary artery end. (C,D) Showing a “fetal type” ductus, which is typical long, wide and tortuous.
aorta, slightly lower than the PDA. A hand angiogram of 1.5–
2ml is performed in RAO and lateral projection or only in
lateral projection in single plane laboratories. In some centers
fluoroscopic guidance only is used (51, 53), although most
centers routinely perform this procedure under angiography
guidance to minimize the risk of complications. Most of the
patients needing PDA closure had type C (tubular) and F (fetal)
types of PDA morphology (54) (Figure 2).
The appropriate device is selected based on echocardiographic
and angiographic measurements (Figure 3). As a rule, the
shortest APO device is used to avoid protrusion of the device in
aorta/pulmonary artery branches. In almost all cases only 2mm
or 4 mm-length devices are used.
The device is positioned under fluoroscopy guidance with
the goal to implant the entire length of the device into the
PDA. Successful positioning is defined by complete occlusion
of the duct and the absence of aortic or LPA obstruction
by echocardiography.
Following release of the device, echocardiographic evaluation
is repeated, paying also particular attention to the tricuspid valve
function. Follow-up echocardiography is performed within 24 h
after procedure.
ANESTHESIA MANAGEMENT
Anesthesia in this high-risk population presents a number
of challenges for the anesthesia team. The cardiac catheter
laboratory (CCL) can be a hostile environment for these fragile
patients. Ambient temperature cannot be easily controlled. The
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FIGURE 3 | PDA morphology and size are extremely variable in premature babies. Angiogram helps to delineate duct features, accurately measures both PDA’s aortic
and pulmonary ends and choose the most appropriate device. Angiogram performed through a catheter via RV—MPA—PDA—Descending aorta. Six types of
described PDA morphologies have been demonstrated in figures (A–F). (A) Relatively long duct with mid-course constriction. (B) Long and tortuous duct with
pulmonary end constriction. (C) Long and tortuous duct with widely open pulmonary and aortic ends. (D) Short duct with pulmonary end constriction and LPA origin
stenosis. (E) Extremely large and dilated duct (note that its diameter is bigger than descending aorta) and (F) Long and tortuous duct with variable diameter along its
course (RV, right ventricle; MPA, main pulmonary artery; LPA, left pulmonary artery; PDA, patent ductus arteriosus).
warming blanket should be turned on prior to patient arrival and
central patient temperature monitoring is mandatory. Imaging
equipment makes patient access during the procedure difficult
so patient positioning (arms up) should be optimized prior to
allowing equipment in.
Ensure easy access to an intravenous (IV) line, preferably in an
upper limb. Two IV lines are essential; one to continue dextrose
containing maintenance fluid and the other for fluids and/or
drugs required during the procedure. IV access should be secured
in the NICU to minimize time in the cardiac catheter laboratory.
Accurate monitoring of end-tidal carbon dioxide
(ETCO2) can be difficult. It is advisable to have an
endotracheal tube (ETT) with minimal leak and minimize
circuit dead-space.
There are two periods of potential instability during the
procedure however both are generally short-lived and respond
quickly to the measures described. Firstly, when the device is
positioned in the duct, there is a sudden drop in pulmonary
blood flow with a corresponding drop in ETCO2 measurements
and peripheral saturations. It is advisable to briefly increase the
inspired oxygen concentration to maintain acceptable saturation
levels until the circulation adjusts. It may also help to temporarily
lower the positive end-expiratory pressure to promote forward
flow from the right ventricle.
The second is during echocardiography to confirm device
position. This can impact significantly on ventilation requiring
an increase in ventilatory pressures and the echocardiographer
to echo intermittently to ensure adequate ventilation
during assessment.
REPORTS IN THE LITERATURE ON
VENOUS-ONLY ACCESS TCPC IN
PREMATURE INFANTS
Morville et al. reported successful transcatheter closure of PDA in
32 out of 34 infants under 2,500 g and in their series two patients
had major complications: (1) death from hemopericardium and
(2) LPA obstruction that required surgical device removal (60).
Zahn et al. reported successful PDA closure via transcatheter
route in 20 out of 23 premature infants (mean weight 1,250 g;
range 755–2,380) and two patients were reported to have
complications: (1) LPA stenosis that required stent placement at
3 months of age and (2) transient descending aortic obstruction
that was relieved by device manipulation (43, 61). In a small
case series 16 patients, Baspinar et al. reported successful closure
of PDA in 13 premature infants with a mean weight of 1,000
± 300 g and three patients were reported to have significant
complications including: (1) death from cardiac perforation in
one patient and (2) device embolization in two patients, which
were retrieved successfully by transcatheter route. These patients
needed subsequent surgical closure of the PDA (62). Rodriguez
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TABLE 1 | Success rate and major complications from transcatheter closure of PDA in preterm infants (43, 49, 50, 52, 60–62).
Author (ref) Mean weight (grams) No of procedures Success rate Major complications (no of cases)
Baspinar et al. (62) 1,700 ± 300g 16 13/16 (81%) Device embolization (2);
Death from cardiac perforation (1)
Zahn et al. (43, 61) 1,250 g (range: 755–2,380 g) 23 20/23 (87%) Transient descending aortic obstruction (1);
LPA stenosis needing stenting (1)
Morville et al. (60) <2,500 g; 17 under 1,200 g 34 32/34 (94%) Death from hemopericardium (1);
LPA obstruction requiring surgical device removal (1)
Sathanandam et al. (50) <2,000 g 82 80/82 (98%) Death from inferior vena cava laceration (1);
Severe LPA stenosis needing device retrieval (1);
Pericardial effusion needing drainage (1)
Rodriguez Ogando et al. (49) 1,260 g (range: 1,000–1,980 g) 27 27 (100%) No major complications reported
Regan et al. (52) 1,200 g (range: 1,025–1,700 g) 64 63/64 (98%) Severe LPA stenosis needing device retrieval (2);
Aortic arch obstruction needing re-intervention (1);
Ogando et al. reported 100% success rate with PDAdevice closure
in 27 preterm infants with a median weight of 1,260 g (range
1,000–1,980) and no major complications were reported (49).
In one of the largest published study so far, Sathanandam
et al. reported successful closure of 80 out of 82 preterm
infants weighing <2,000 g and three patients were reported
to have major complications: (1) death from inferior vena
cava laceration, (2) severe LPA stenosis needing manipulation
of device, and (3) pericardial effusion needing drainage
percutaneously (50).
Recently from one of the largest multi-center study involving
147 infants, 64 undergoing transcutaneous PDA closure or 83
with surgical ligation, Regan et al. reported that transcatheter
closure of PDA offers sustained improvement in morbidity
as compared to surgical ligation through a reduction in
post-procedural mechanical ventilation time that is significant
throughout the total NICU stay. They reported successful closure
of PDA in 63 out of 64 preterm infants with ameanweight 1,200 g
(range 1,025–1,700) and three patients were reported to have
complications: (1) severe LPA stenosis needing device retrieval
and (2) aortic arch obstruction needing re-intervention (51). Six
cases had mild LPA stenoses due to protrusion of the device, with
a maximum velocity of 2.5 m/s on CW Doppler interrogation,
which all resolved within 3–12 months during the follow-up (52).
The results from these reports are encouraging and provide
evidence that transcatheter closure PDA in preterm infants
is feasible with an acceptable complications rate (Table 1)
and at least study comparing results with surgical ligation
demonstrate that outcomes were better with device closure
and complications were less compared to surgical ligation (52).
However, none of these reports provide long-term outcomes
(especially death or BPD) and the impact on neurodevelopment
is unknown.
COMPLICATIONS
One of the most frequent complications is left pulmonary
artery (LPA) obstruction due to protrusion of the device. In
a 1,000 g infant, the LPA diameter is ∼3mm whereas the
APO retention discs for the 4 and 5 mm-devices are 5.25 and
6.5mm, respectively. Despite the goal to implant the whole
device inside the duct itself, protrusion of the proximal disk
may occur especially in patients with a large duct and restriction
at the pulmonary end. In cases with significant LPA stenosis
(max velocity >2 m/s on continuous wave (CW) Doppler
interrogation) diagnosed before the device is released it is
recommended to reposition it or to change it for a shorter and/or
a smaller device. Significant LPA stenosis has been described with
AVP II requiring LPA stenting (61). When the LPA stenosis is
mild, the device can sometimes be released as this will resolve in
most of the cases during follow-up (49).
Coarctation of the aorta related to the device is an uncommon
complication. It is often diagnosed with transthoracic
echocardiography (TTE) during implantation of the device
and repositioning is required in such cases. Similar to LPA
stenosis, mild coarctation may resolve with patient’s growth.
However, significant coarctation may develop, necessitating
surgical repair (52) (Figure 4).
Device embolization has also been reported during,
immediately after and up to 9 days post procedure (48, 49, 63),
usually in patients over 1,200 g with a large PDA. The device can
be retrieved percutaneously in most cases through a 4Fr or 5Fr
sheath (52).
Tricuspid valve injury has been reported and it is often due
to chordae rupture from the catheter when the tricuspid valve
is crossed.
Rupture and/or dissection of inferior vena cava has been
reported as a fatal complication (50). Position of the wire
during the femoral vein access should be checked by fluoroscopy
before advancing any sheath to minimize this potentially
life-threatening complication.
Morville et al. reported fatal cardiac perforation in a 680 g
patient. During the procedure the right ventricle was perforated
by a 4Fr catheter over a 0.018 Terumo wire, creating a
hemopericardium (64). Use of 0.014 soft coronary wire should
be advocated in the smallest patients.
There is an existing gap in knowledge in comparing the
immediate post-PDA closure complication rates among those
undergoing surgical ligation vs. transcatheter occlusion and at
this stage no studies have been published comparing such data.
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FIGURE 4 | Complications encountered after PDA device closure. (A) Shows LPA origin stenosis following percutaneous closure, which is fully resolved 5 months
after follow-up (B). (C) Mild aortic coarctation after device deployment, which is fully resolved after 11 months of follow-up (D). (E) Tricuspid valve trauma noted after
successful PDA device closure. (F) Tricuspid regurgitation is trivial 12 months after the procedure.
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FUTURE DIRECTION
Transcatheter closure of PDA intuitively appear to be
advantageous in ELBW infants. A refined an echocardiographic
guided antegrade femoral venous approach, which can be
performed at the bedside with little or no contrast and minimal
radiation exposure has been developed. Early results from the
US ADO II-AS multicenter clinical trial are encouraging. We
are cautiously optimistic that ongoing modifications in device
design and techniques may ultimately make this a routine
bedside procedure performed in the neonatal intensive care
unit. However, carefully designed prospective randomized trials
studying short- and long-term outcomes will be necessary
to determine whether this novel therapy should be the new
standard of care. Whether early transcutaneous closure of PDA
in ELBW infants will result in improved short- and long- term
outcomes, less BPD, improved neurodevelopment, or better long
term renal function remains to be seen.
CONCLUSION
Transcatheter PDA closure in preterm ELBW infants is
technically feasible with high PDA occlusion success rates
and acceptable complication rates. The current technique and
available devices apply for most of the population, including
extremely low birth weight infants. Although follow up studies
report excellent short and medium term outcomes, they need to
be further tested in the prospective, well-designed and probably
randomized controlled trials comparing the results and outcomes
of this technique vs. current treatment strategies including
medical treatment. This innovative technique is being adopted
in increasing number of centers across the globe, however
further experience is needed. There is an urgent need for
multicenter studies and registries to better clarify the results,
optimal timing for this procedure, and to study the short-term
and long-term outcomes before this can be considered as an
alternative first line therapy, when PDA closure is required in
ELBW infants.
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